IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
Relative valuation derived from Healthcare sector median benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Multiples adjusted for extreme outliers and non-recurring volatility.
Auditing capital efficiency...
Quality Profile Audit
Score: 50GRADE C+
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation.
Return on Equity
Profit generated per dollar of shareholder equity
9.7%
Sector: -43.5%
Dividend Analysis audit
No Dividend
This company does not currently pay a dividend.
Analyst Projections
Analyst Consensus
Unlock Valuation Tools
Sign up for free access to institutional-quality research tools.
Based on our 6-factor quantitative model, ALIGN TECHNOLOGY INC (ALGN) receives a "Hold" rating with a composite score of 48.2/100, ranked #1158 out of 4446 stocks. Key factor scores: Quality 50/100, Value 58/100, Momentum 54/100. This is quantitative analysis only — not investment advice.
ALIGN TECHNOLOGY INC (ALGN) Stock Analysis — April 2026 Rating, Price, and Forecast
Company Overview — What Does ALIGN TECHNOLOGY INC Do?
Align Technology, Inc., a medical device company, designs, manufactures, and markets Invisalign clear aligners and iTero intraoral scanners and services for orthodontists and general practitioner dentists, and restorative and aesthetic dentistry. It operates in two segments, Clear Aligner; and Scanners and Services. The Clear Aligner segment consists of comprehensive products, including Invisalign comprehensive treatment that addresses the orthodontic needs of teenage patients, such as mandibular advancement, compliance indicators, and compensation for tooth eruption; and Invisalign First Phase I and Invisalign First Comprehensive Phase 2 package for younger patients generally between the ages of seven and ten years, which is a mixture of primary/baby and permanent teeth. This segment's non-comprehensive products comprise Invisalign moderate, lite and express packages, and Invisalign go; and non-case products include retention products, Invisalign training fees, and sales of ancillary products, such as cleaning material, and adjusting tools used by dental professionals during the course of treatment. The Scanners and Services segment offers iTero scanner, a single hardware platform with software options for restorative or orthodontic procedures; restorative software for general practitioner dentists, prosthodontists, periodontists, and oral surgeons; and software for orthodontists for digital records storage, orthodontic diagnosis, and for the fabrication of printed models and retainers. This segment also provides computer-aided design and computer-aided manufacturing services; ancillary products, such as disposable sleeves for the wand; iTero model and dies; third party scanners and digital scans; Invisalign outcome simulator, a chair-side and cloud-based application for the iTero scanner; Invisalign progress assessment tool; and TimeLapse technology, which allows doctors or practitioners to compare a patient's historic 3D scans to the present-day scan. The company sells its products in the United States, Switzerland, China, and internationally. Align Technology, Inc. was incorporated in 1997 and is headquartered in Tempe, Arizona. ALIGN TECHNOLOGY INC (ALGN) is classified as a large-cap stock in the Healthcare sector, specifically within the Medical Equipment industry. The company is led by CEO Joseph M. Hogan and employs approximately 23,200 people, headquartered in San Jose, Arizona. With a market capitalization of $12.3B, ALGN is one of the prominent companies in the Healthcare sector.
ALIGN TECHNOLOGY INC (ALGN) Stock Rating — Hold (April 2026)
As of April 2026, ALIGN TECHNOLOGY INC receives a Hold rating with a composite score of 48.2/100 and 3 out of 5 stars from the Blank Capital Research quantitative model.ALGN ranks #1,158 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, ALIGN TECHNOLOGY INC ranks #86 of 838 stocks, placing it in the top quartile of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).
ALGN Stock Price and 52-Week Range
ALIGN TECHNOLOGY INC (ALGN) currently trades at $173.14. The stock lost $1.39 (0.8%) in the most recent trading session. The 52-week high for ALGN is $208.31, which means the stock is currently trading -16.9% from its annual peak. The 52-week low is $122.00, putting the stock 41.9% above its annual trough. Recent trading volume was 785K shares, suggesting relatively thin trading activity.
Is ALGN Overvalued or Undervalued? — Valuation Analysis
ALIGN TECHNOLOGY INC (ALGN) carries a value factor score of 58/100 in the Blank Capital model, indicating fair valuation relative to historical norms. The trailing price-to-earnings ratio is 30.46x, compared to the Healthcare sector average of 23.63x — a premium of 29%. The price-to-book ratio stands at 2.94x, versus the sector average of 2.75x. The price-to-sales ratio is 3.00x, compared to 1.66x for the average Healthcare stock. On an enterprise value basis, ALGN trades at 21.52x EV/EBITDA, versus 6.34x for the sector.
Overall, ALGN's valuation appears roughly in line with sector benchmarks, suggesting the market is pricing the stock fairly given its current fundamentals and growth trajectory. Neither deep value nor significantly overpriced, the stock occupies a middle ground on valuation.
ALIGN TECHNOLOGY INC Profitability — ROE, Margins, and Quality Score
ALIGN TECHNOLOGY INC (ALGN) earns a quality factor score of 50/100, indicating solid business quality with consistent operational execution. The return on equity (ROE) is 9.7%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at 6.3% versus the sector average of -33.1%.
On a margin basis, ALIGN TECHNOLOGY INC reports gross margins of 68.3%, compared to 71.5% for the sector. The operating margin is 13.9% (sector: -66.1%). Net profit margin stands at 9.8%, versus -58.7% for the average Healthcare stock. Revenue growth is running at -3.2% on a trailing basis, compared to 10.6% for the sector. The overall profitability profile is adequate, though there may be room for margin expansion.
ALGN Debt, Balance Sheet, and Financial Health
ALIGN TECHNOLOGY INC has a debt-to-equity ratio of 54.0%, compared to the Healthcare sector average of 32.0%. Leverage is within a manageable range for the industry, though investors should monitor debt trends over time. The current ratio is 1.36x, suggesting adequate working capital coverage. Total debt on the balance sheet is $0. Cash and equivalents stand at $1.00B.
ALGN has a beta of 1.26, meaning it is more volatile than the broader market — a $10,000 investment in ALGN would be expected to move 26.0% more than the S&P 500 on any given day. The stability factor score for ALIGN TECHNOLOGY INC is 46/100, reflecting average volatility within the normal range for its sector.
ALIGN TECHNOLOGY INC Revenue and Earnings History — Quarterly Trend
In TTM 2026, ALIGN TECHNOLOGY INC reported revenue of $3.97B and earnings per share (EPS) of $5.66. Net income for the quarter was $391M. Gross margin was 68.3%. Operating income came in at $553M.
In FY 2025, ALIGN TECHNOLOGY INC reported revenue of $4.03B and earnings per share (EPS) of $5.66. Net income for the quarter was $410M. Gross margin was 67.2%. Revenue grew 0.9% year-over-year compared to FY 2024. Operating income came in at $546M.
In Q3 2025, ALIGN TECHNOLOGY INC reported revenue of $996M and earnings per share (EPS) of $0.78. Net income for the quarter was $57M. Gross margin was 64.2%. Revenue grew 1.8% year-over-year compared to Q3 2024. Operating income came in at $96M.
In Q2 2025, ALIGN TECHNOLOGY INC reported revenue of $1.01B and earnings per share (EPS) of $1.72. Net income for the quarter was $125M. Gross margin was 69.9%. Revenue grew -1.6% year-over-year compared to Q2 2024. Operating income came in at $163M.
Over the past 8 quarters, ALIGN TECHNOLOGY INC has demonstrated a growth trajectory, with revenue expanding from $1.03B to $3.97B. Investors analyzing ALGN stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.
ALGN Dividend Yield and Income Analysis
ALIGN TECHNOLOGY INC (ALGN) does not currently pay a dividend. This is common among growth-oriented companies in the Medical Equipment industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.
ALGN Momentum and Technical Analysis Profile
ALIGN TECHNOLOGY INC (ALGN) has a momentum factor score of 54/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 35/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 30/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.
ALGN vs Competitors — Healthcare Sector Ranking and Peer Comparison
Comparing ALGN against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full ALGN vs S&P 500 (SPY) comparison to assess how ALIGN TECHNOLOGY INC stacks up against the broader market across all factor dimensions.
ALGN Next Earnings Date
No upcoming earnings date has been announced for ALIGN TECHNOLOGY INC (ALGN) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.
Should You Buy ALGN? — Investment Thesis Summary
ALIGN TECHNOLOGY INC presents a balanced picture with arguments on both sides.
In summary, ALIGN TECHNOLOGY INC (ALGN) earns a Hold rating with a composite score of 48.2/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on ALGN stock.
We'll email you when stocks you follow change their composite rating.
Institutional Research Dossier
ALIGN TECHNOLOGY INC (ALGN) Deep Dive Analysis
Published on March 24, 2026
Action RatingHold
Sections
Executive Summary
Align Technology (ALGN) receives a Hold rating, reflecting a balanced view of its market position and financial performance. While the company maintains a leading position in the clear aligner market and demonstrates strong profitability metrics compared to the broader healthcare sector, concerns regarding recent revenue declines and a relatively high valuation temper enthusiasm. The key takeaway is that ALGN's future success hinges on its ability to reignite growth in a competitive landscape and justify its premium valuation through sustained innovation and market expansion.
The company's innovative products, particularly the Invisalign system and iTero scanners, have disrupted traditional orthodontics. However, recent financial results indicate a slowdown in revenue growth, raising questions about the sustainability of its historical performance. While Align Technology boasts impressive gross and operating margins compared to the healthcare sector, its relatively high P/E ratio suggests that the market has already priced in significant future growth, leaving limited room for error. Therefore, a Hold rating is warranted until there is clearer evidence of a return to robust growth and a more compelling valuation.
Business Strategy & Overview
Align Technology operates primarily through two segments: Clear Aligner and Scanners & Services. The Clear Aligner segment, anchored by the Invisalign system, targets both teenage and adult patients seeking orthodontic solutions. The company's strategy involves continuous product innovation, such as the development of Invisalign First for younger patients and features like mandibular advancement for teenagers. This segment also includes non-comprehensive products like Invisalign Lite and Express, catering to a broader range of orthodontic needs. The Scanners & Services segment focuses on the iTero intraoral scanner, a key tool for digital dentistry. Align's strategy here centers on expanding the applications of the iTero scanner beyond orthodontics to include restorative and aesthetic dentistry. This involves developing software solutions for general practitioners, prosthodontists, and oral surgeons.
A core element of Align's business strategy is its direct-to-consumer (DTC) marketing efforts, which aim to increase awareness and demand for Invisalign. By educating consumers about the benefits of clear aligner therapy, Align seeks to drive traffic to its network of orthodontists and dentists. The company also invests heavily in training and education programs for dental professionals, ensuring they are proficient in using Invisalign and iTero products. This training is crucial for maintaining the quality of treatment and fostering long-term relationships with practitioners.
Align Technology's strategic positioning within the dental industry is centered on digital transformation. By offering a comprehensive suite of digital solutions, including clear aligners, intraoral scanners, and software, Align aims to streamline the orthodontic and dental treatment process. This digital approach offers several advantages, including improved accuracy, efficiency, and patient comfort. The company's product pipeline includes ongoing enhancements to both the Invisalign system and the iTero scanner, with a focus on expanding their capabilities and applications. This includes developing new features for the Invisalign app, improving the accuracy and speed of the iTero scanner, and integrating artificial intelligence into its software solutions.
The industry context for Align Technology is characterized by increasing demand for cosmetic dentistry and a growing awareness of the benefits of clear aligner therapy. The market is becoming increasingly competitive, with new entrants and established players offering alternative clear aligner solutions. Align's ability to maintain its market leadership will depend on its continued innovation, effective marketing, and strong relationships with dental professionals. The company also faces challenges related to regulatory approvals, reimbursement policies, and economic conditions, which can impact demand for its products.
Execution Benchmarks audit
Revenue Growth
YOY expansion rate
-3.2%
Sector: 10.6%
-130% VS SCTR
Economic Moat Analysis
Align Technology possesses a narrow economic moat, primarily derived from intangible assets and switching costs. The Invisalign brand enjoys significant recognition and reputation among both dental professionals and consumers, representing a valuable intangible asset. This brand equity allows Align to command a premium price and maintain a leading market share. However, the moat is not wide due to the increasing competition in the clear aligner market, which limits Align's pricing power and market dominance.
Switching costs also contribute to Align's narrow moat. Once a dental professional invests in the iTero scanner and integrates Invisalign into their practice, switching to a competitor's system can be costly and disruptive. The learning curve associated with new systems, the need to retrain staff, and the potential loss of patient referrals create barriers to switching. However, these switching costs are not insurmountable, as competitors offer incentives and support to encourage dental professionals to adopt their systems.
Network effects play a limited role in Align's moat. While the company benefits from a large network of Invisalign-trained providers, the value of this network to individual practitioners is not as strong as in other industries with network effects. The primary benefit is access to a larger pool of potential patients, but this is offset by the increasing competition among Invisalign providers. Furthermore, the network effect is not as pronounced for consumers, as they are primarily concerned with the quality and effectiveness of the treatment, rather than the size of the provider network.
Align Technology does not possess a significant cost advantage or benefit from efficient scale. While the company has achieved economies of scale in its manufacturing operations, these advantages are not substantial enough to create a wide moat. Competitors can also achieve similar cost efficiencies through their own manufacturing processes. Furthermore, the clear aligner market is not characterized by natural monopolies or significant barriers to entry, which limits Align's ability to achieve efficient scale.
The increasing competition in the clear aligner market is eroding Align's moat. New entrants are offering lower-priced alternatives, putting pressure on Align's pricing and market share. Furthermore, some competitors are developing innovative technologies that could challenge Align's technological leadership. To maintain its competitive advantage, Align must continue to invest in research and development, strengthen its brand, and enhance its relationships with dental professionals.
Financial Health & Profitability
Align Technology's financial health presents a mixed picture. The company boasts strong gross and operating margins compared to the healthcare sector, with a gross margin of 68.3% and an operating margin of 13.9% versus sector averages of 71.9% and -65.2%, respectively. These figures indicate efficient operations and a strong pricing power. However, revenue growth has been a concern, with a -3.2% decline in the latest TTM period, contrasting sharply with the sector's 10.7% growth. This decline raises questions about the sustainability of Align's historical performance and its ability to compete in an increasingly competitive market.
The company's profitability metrics, such as ROE (9.7%), are significantly better than the sector average (-42.5%), demonstrating its ability to generate returns on equity. Align Technology also maintains a healthy balance sheet with $1.00 billion in total cash and no debt, providing financial flexibility for investments and acquisitions. The current ratio of 1.36 indicates sufficient liquidity to meet short-term obligations.
Analyzing the quarterly financial history reveals a fluctuating trend in revenue and net income. While revenue remained relatively stable around $1 billion per quarter, net income experienced more volatility. The gross margin has also shown some variability, ranging from 64.2% to 71.2%. The operating margin has followed a similar pattern, fluctuating between 9.7% and 17.3%. These fluctuations suggest that Align's financial performance is sensitive to factors such as product mix, pricing pressures, and marketing expenses.
Free cash flow (FCF) generation has been inconsistent. The most recent TTM FCF is only $35.10 million, a significant decrease from the $262.07 million reported for FY2024. This decline in FCF raises concerns about the company's ability to fund future growth initiatives and return capital to shareholders. The lack of FCF data for recent quarters makes it difficult to assess the underlying drivers of this decline and its potential impact on Align's long-term financial health.
Overall, Align Technology's financial health is characterized by strong profitability and a healthy balance sheet, but concerns remain regarding revenue growth and free cash flow generation. The company's ability to address these challenges will be crucial for maintaining its financial stability and creating shareholder value.
Valuation Assessment
Align Technology's valuation is a key consideration in assessing its investment potential. The company's P/E ratio of 30.6x is higher than the healthcare sector average of 24.3x, suggesting that the market has priced in expectations for future growth. This premium valuation reflects Align's leading market position and strong profitability, but it also implies that the stock may be vulnerable to downside risk if growth slows or margins decline.
The EV/EBITDA multiple of 5.7x is slightly lower than the sector average of 6.4x. This suggests that Align Technology may be relatively undervalued on an enterprise value basis. However, EV/EBITDA can be misleading for companies with significant cash balances or debt, so it should be interpreted with caution.
Given the company's recent revenue decline of -3.2%, the current valuation appears stretched. A high P/E ratio coupled with negative revenue growth suggests that the market is overly optimistic about Align's future prospects. To justify its premium valuation, Align Technology needs to demonstrate a return to robust revenue growth and maintain its strong profitability.
A discounted cash flow (DCF) analysis would be necessary to determine a more precise fair value for Align Technology. However, based on the available data, it appears that the stock is currently trading at a premium to its intrinsic value. The market's expectations for future growth may be too high, given the increasing competition and the recent slowdown in revenue growth.
In summary, Align Technology's valuation is a concern. The high P/E ratio and negative revenue growth suggest that the stock is overvalued. While the company's strong profitability and healthy balance sheet provide some support for its valuation, investors should be cautious about paying a premium for future growth that may not materialize.
Risk & Uncertainty
Several risks and uncertainties could impact Align Technology's business and financial performance. Increased competition in the clear aligner market poses a significant threat. As new entrants offer lower-priced alternatives and develop innovative technologies, Align's market share and pricing power could be eroded. The company must continue to invest in research and development and strengthen its brand to maintain its competitive advantage.
Regulatory risks are also a concern. The dental industry is subject to various regulations related to product safety, marketing practices, and data privacy. Changes in these regulations could increase Align's compliance costs and limit its ability to market its products effectively. Furthermore, regulatory approvals for new products or features could be delayed, impacting the company's growth prospects.
Economic conditions can also affect demand for Align Technology's products. During economic downturns, consumers may postpone or forgo elective dental procedures, such as orthodontic treatment. This could lead to a decline in sales and profitability. The company's international operations are also exposed to currency risks, which could negatively impact its financial results.
The company's reliance on a network of dental professionals creates a concentration risk. If Align Technology loses the support of a significant number of practitioners, its sales and market share could decline. The company must maintain strong relationships with its network of providers and provide them with the training and support they need to effectively use its products.
Bulls Say / Bears Say
The Bull Case
BULL VIEWAlign Technology's strong brand recognition and leading market share in the clear aligner market provide a significant competitive advantage, allowing it to command premium pricing and maintain profitability.
BULL VIEWThe company's innovative iTero scanner and digital workflow solutions are transforming the dental industry, creating new opportunities for growth and expanding its addressable market.
BULL VIEWAlign Technology's healthy balance sheet, with significant cash reserves and no debt, provides financial flexibility to invest in research and development, pursue strategic acquisitions, and return capital to shareholders.
The Bear Case
BEAR VIEWIncreasing competition from lower-priced alternatives and new entrants in the clear aligner market will erode Align Technology's market share and pricing power, leading to lower profitability.
BEAR VIEWThe company's high valuation, with a P/E ratio above the sector average, is unsustainable given its recent revenue decline and the potential for slower growth in the future.
BEAR VIEWA slowdown in consumer spending due to economic uncertainty could negatively impact demand for Align Technology's elective dental procedures, leading to lower sales and earnings.
About the Author
Marques Blank
Founder & Chief Investment Officer, Blank Capital
Marques brings 15 years of institutional finance and investing experience, having overseen financial planning for a $1.6B defense business unit. He developed the proprietary 6-factor quantitative model used to score ALGN and 4,400+ other equities.
ALIGN TECHNOLOGY INC exhibits a 89% valuation premium relative to institutional benchmarks. This represents a potential valuation overextension based on current multiples.
Return on Assets
Efficiency of asset utilization
6.3%
Sector: -33.1%
Gross Margin
Pricing power and cost efficiency
68.3%
Sector: 71.5%
Operating Margin
Core business profitability
13.9%
Sector: -66.1%
Net Margin
Bottom-line profitability
9.8%
Sector: -58.7%
Factor Methodology
The Quality factor evaluates the persistence and magnitude of cash flows. Companies with scores >70 exhibit superior competitive moats and financial resilience through economic cycles.
